MARKET

SGMO

SGMO

SANGAMO THERAPEU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.97
+0.16
+1.63%
Closed 19:15 09/25 EDT
OPEN
9.80
PREV CLOSE
9.81
HIGH
10.06
LOW
9.74
VOLUME
1.50M
TURNOVER
--
52 WEEK HIGH
13.20
52 WEEK LOW
4.810
MARKET CAP
1.41B
P/E (TTM)
-12.0848
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Sangamo Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Threshold
Investor's Business Daily · 09/15 14:48
Is Biogen Stock a Buy?
MotleyFool.com · 09/15 06:18
Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. Kenneth Hillan, an accomplished biotechnology executive, to the Company's Board of Directors.
Business Wire · 09/11 12:30
Sangamo Therapeutics Getting Closer To Key Technical Benchmark
Investor's Business Daily · 09/10 16:11
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:
Business Wire · 09/02 21:15
How Much Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Paying Its CEO?
Sandy Macrae became the CEO of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) in 2016, and we think it's a good time to look...
Simply Wall St. · 09/01 20:47
BioMarin Declining Factor Levels Unlikely To Impact Uniqure Or Sangamo Phase 3 Hemophilia Trials
BioMarin BLA for Valrox received a CRL last week.  Two years of data is now needed before resubmission.Three other hemophilia gene therapies from Pfizer and Uniqure are in Phase III.Factor levels, lead-in studies, consistent study design and annual bleed rates are all important.  It is clear the FDA cares about predicted durability.
Seekingalpha · 08/26 14:26
Regenerative Medicine: Does BioMarin Complete Response Letter Change The Outlook?
Seeking Alpha - Article · 08/25 17:24
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SGMO. Analyze the recent business situations of SANGAMO THERAPEU through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SGMO stock price target is 20.13 with a high estimate of 36.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 288
Institutional Holdings: 83.47M
% Owned: 59.21%
Shares Outstanding: 140.99M
TypeInstitutionsShares
Increased
77
9.49M
New
45
-3.80M
Decreased
47
3.17M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
President/Chief Executive Officer/Director
Alexander Macrae
Chief Financial Officer/Executive Vice President
Sung Lee
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Gary Loeb
Chief Financial Officer
Prathyusha Durabaibu
Executive Vice President
D. Mark McClung
Executive Vice President
R. Andrew Ramelmeier
Vice President - Finance
Prathyusha Duraibabu
Director
Kenneth Hillan
Independent Director
Robert Carey
Independent Director
Stephen Dilly
Independent Director
John Markels
Independent Director
James Meyers
Independent Director
H. Stewart Parker
Independent Director
Saira Ramasastry
Independent Director
Karen Smith
Independent Director
Joseph Zakrzewski
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SGMO
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Sangamo Therapeutics Inc stock information, including NASDAQ:SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.